Latest Breaking News On - Ulcerative colitis development program to takeda - Page 1 : comparemela.com

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage.

Marc blausteinMark smithGreg perryAmerican college of gastroenterologyFinch therapeutics group incUlcerative colitis development program to takedaClinical developmentTherapeutics groupHuman first discoveryChief executive officerChief financial officerChief operating officerDigestive disease weekPositive topline resultsLabel trialWeek efficacy